Modified U7 snRNA Splicing Modulation for Neuromuscular Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNA-based therapeutic strategies for neuromuscular diseases, such as Duchenne muscular dystrophy and myotonic dystrophy, face challenges in efficiently modulating splicing pathways and require repeated treatments, while existing exon skipping techniques using antisense oligonucleotides often fail to correctly interact with the splicing machinery.
Innovation Solution
A modified U7 snRNA is developed, incorporating a smOPT domain and an antisense sequence that interacts with the U7 loop, potentially enhanced by a 'kiss domain' to ensure correct folding and efficient targeting of the spliceosome, allowing for specific modulation of splicing events and treatment of neuromuscular diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antisense oligonucleotides are used for exon skipping, then splicing modulation is attempted, but correct interaction with the splicing machinery is achieved poorly
Solution Approach 1:
The patent uses U7 snRNA as an intermediary molecule to mediate between the antisense sequence and the splicing machinery. The U7 snRNA structure includes a U7 loop that directly interacts with the spliceosome, while the antisense sequence targets the pre-mRNA, thereby improving the reliability of splicing modulation through a dual-function mediator structure
Solution Approach 2:
The invention creates a composite molecular structure by combining the U7 snRNA scaffold with antisense sequences. This composite structure integrates the splicing machinery interaction capability of U7 snRNA with the target-specific binding capability of antisense sequences, achieving both structural stability and functional efficacy
2Adaptability or versatility
If RNA-based therapeutic strategies are used to modulate splicing pathways, then treatment of neuromuscular diseases is enabled, but repeated treatments are required
Solution Approach 1:
The patent employs viral vectors to deliver the modified U7 snRNA construct into patient cells before the disease progresses significantly. The U7 snRNA is then expressed continuously from the integrated viral genome, establishing long-term splicing modulation that persists throughout the patient's life, eliminating the need for repeated treatments
Solution Approach 2:
The modified U7 snRNA construct is designed to be self-sustaining within the patient's cells. Once delivered via viral vector, the construct uses the cell's own transcriptional machinery to produce functional U7 snRNA molecules continuously, creating a self-perpetuating therapeutic effect that maintains splicing correction without external intervention
3Productivity
If exon skipping techniques are used to treat Duchenne muscular dystrophy, then dystrophin expression is attempted, but functional restoration is insufficient
Solution Approach 1:
The patent applies local quality by designing the U7 snRNA with distinct functional domains: the U7 loop region is optimized for precise splice site recognition and interaction with the spliceosome, while the antisense sequence is customized to target specific exon regions. This localized functional specialization ensures both accurate splicing and efficient dystrophin production
Solution Approach 2:
The invention optimizes multiple parameters of the U7 snRNA structure, including the length and sequence of the antisense region, the composition of the U7 loop, and the overall molecular architecture. These parameter optimizations enhance both the precision of splicing recognition and the efficiency of functional dystrophin protein production
4Stability of the object's composition
If modified U7 snRNA with kiss domain is constructed, then correct folding is achieved, but off-target effects are reduced
Solution Approach 1:
The kiss domain acts as an intermediary structural element that mediates the correct folding of the U7 snRNA molecule. This domain facilitates proper spatial arrangement of the antisense sequence and U7 loop, ensuring high-specificity binding to the target pre-mRNA while preventing off-target interactions through accurate molecular geometry
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified U7 snRNA effectively promotes exon skipping, inclusion, or eradication of deleterious mRNAs, leading to functional restoration of proteins like dystrophin and SMN, with long-lasting effects and reduced off-target effects, improving splicing accuracy and muscle cell differentiation.
Implementation Method 1
An interaction between the antisense moiety and the U7 loop is required to obtain active U7-derived snRNPs
Implementation Method 2
redirected to the spliceosome by replacement of the endogenous sm-binding domain with the one of the U1 snRNA
Data Source
Figure 1a~1d
Figure 2a~2b
Figure 2c
AI summary
The present invention relates to a method to improve the activity of engineered U7 snRNAs used in the context of RNA-based therapeutics; particularly in exon skipping, exon inclusion, and mRNA eradication strategies. The resulting modified U7 snRNAs are useful for treating neuromuscular diseases, in particular Duchenne neuromuscular dystrophy, myotonic dystrophy DM1 and spinal muscular atrophy.